Internal medicine

Clinical endpoint

Pomalidomide

Dexamethasone

Interim analysis

Surgery

Oncology

Multiple myeloma

Lenalidomide

Clinical trial

Medicine

The Lancet Haematology

The results from this unplanned, FDA-requested, interim analysis showed that the benefit–risk profile of pembrolizumab plus pomalidomide and dexamethasone is unfavourable for patients with relapsed or refractory multiple myeloma.

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial